Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity
Autore:
Serretti, A; Zanardi, R; Rossini, D; Cusin, C; Lilli, R; Smeraldi, E;
Indirizzi:
Vita Salute Univ, San Raffaele Inst, Dept Psychiat, Milan, Italy Vita Salute Univ Milan Italy Raffaele Inst, Dept Psychiat, Milan, Italy
Titolo Testata:
MOLECULAR PSYCHIATRY
fascicolo: 5, volume: 6, anno: 2001,
pagine: 586 - 592
SICI:
1359-4184(200109)6:5<586:IOTHAS>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
BIPOLAR AFFECTIVE-DISORDER; COLLABORATIVE RESEARCH-PROGRAM; OBSESSIVE-COMPULSIVE DISORDER; SUICIDAL-BEHAVIOR; FUNCTIONAL POLYMORPHISM; DOPAMINERGIC PATHWAYS; POSSIBLE ASSOCIATION; ALLELIC VARIATION; DEPRESSION; PROMOTER;
Keywords:
tryptophan hydroxylase; serotonin transporter; pindolol; fluvoxamine; mood disorders; antidepressant treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
65
Recensione:
Indirizzi per estratti:
Indirizzo: Zanardi, R Vita Salute Univ, Ist Sci H San Raffaele, Dept Psychiat, Via Stamira Ancona 20, I-20127 Milan, Italy Vita Salute Univ Via Stamira Ancona 20 Milan Italy I-20127 aly
Citazione:
A. Serretti et al., "Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity", MOL PSYCHI, 6(5), 2001, pp. 586-592

Abstract

The aim of the present study was to test a possible effect of the A218C tryptophan hydroxylase (TPH) gene variant on the antidepressant activity of fluvoxamine in a sample of major and bipolar depressives, with or without psychotic features. Two hundred and seventeen inpatients were treated with fluvoxamine 300 mg and either placebo or pindolol in a double blind design for 6 weeks. The severity of depressive symptoms was weekly assessed with theHamilton Rating Scale for Depression. TPH allelic variants were determinedin each subject by using a PCR-based technique. No significant finding wasobserved in the overall sample as well as in the pindolol group, while TPH*A/A was associated with a slower response to fluvoxamine treatment in subjects not taking pindolol (P = 0.001). This effect was independent from the previously reported influence of 5-HTTLPR polymorphism. If confirmed, theseresults may shed further light on the genetically determined component of the response to pharmacological treatments, thus helping the clinician to individualize each patient's therapy according to their genetic pattern.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 05:00:26